Can retooled Pfizer deliver on R&D promises?

Pfizer ($PFE) CEO Ian Read is long on promises of a sunny R&D future. But its near-term pipeline offers iffy benefits, and Read hasn't clearly outlined his approach to juggling internal research with buying and licensing prospective products. Report